Central Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?

Current Hypertension Reports

Volumn 18, Issue 2, 2016, Pages 1-11

  Cagnoni, Francesca ^a,b   Destro, Maurizio ^a   Bontempelli, Erika ^a   Locatelli, Giovanni ^a   Hering, Dagmara ^b   Schlaich, Markus P ^b  

^a Department of Medical Science   (Italy)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

AF; Arrhythmia; Denervation; Moxonidine; SNS; Sympathetic

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; MOXONIDINE;

ABLATION THERAPY; ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ATRIAL FIBRILLATION; CENTRAL SYMPATHETIC INHIBITION; CLINICAL RESEARCH; COMORBIDITY; CONGESTIVE HEART FAILURE; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DENERVATION; NEUROMODULATION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PULMONARY VEIN ISOLATION; RADIOFREQUENCY ABLATION; RADIOFREQUENCY ABLATION DEVICE; REVIEW; SLEEP DISORDERED BREATHING; ANIMAL; ARRHYTHMIAS, CARDIAC; DENERVATION; KIDNEY; SURGERY; TREATMENT OUTCOME;

ANIMALS; ARRHYTHMIAS, CARDIAC; DENERVATION; HUMANS; HYPERTENSION; KIDNEY; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84958176955     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0619-0     Document Type: Review

References (112)

1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837–47. doi:10.1161/circulationaha.113.005119.
2. Ardell JL. The cardiac neuronal hierarchy and susceptibility to arrhythmias. Heart Rhythm. 2011;8(4):590–1. doi:10.1016/j.hrthm.2010.12.019.
3. Chen PS, Tan AY. Autonomic nerve activity and atrial fibrillation. Heart Rhythm. 2007;4(3 Suppl):S61–4. doi:10.1016/j.hrthm.2006.12.006.
4. Janes RD, Brandys JC, Hopkins DA, Johnstone DE, Murphy DA, Armour JA. Anatomy of human extrinsic cardiac nerves and ganglia. Am J Cardiol. 1986;57(4):299–309.
5. Armour J, Hopkins D. Anatomy of the extrinsic efferent autonomic nerves and ganglia innervating the mammalian heart. In: Press NYOU, editor. Nervous control of cardiovascular function., 1984. p. 21-45.
6. Kawashima T. The autonomic nervous system of the human heart with special reference to its origin, course, and peripheral distribution. Anat Embryol (Berl). 2005;209(6):425–38. doi:10.1007/s00429-005-0462-1.
7. Baron R, Janig W, With H. Sympathetic and afferent neurones projecting into forelimb and trunk nerves and the anatomical organization of the thoracic sympathetic outflow of the rat. J Auton Nerv Syst. 1995;53(2-3):205–14.
8. Ellison JP, Williams TH. Sympathetic nerve pathways to the human heart, and their variations. Am J Anat. 1969;124(2):149–62. doi:10.1002/aja.1001240203.
9. Page PL, Dandan N, Savard P, Nadeau R, Armour JA, Cardinal R. Regional distribution of atrial electrical changes induced by stimulation of extracardiac and intracardiac neural elements. J Thorac Cardiovasc Surg. 1995;109(2):377–88.
10. Taniguchi T et al. Cutaneous distribution of sympathetic postganglionic fibers from stellate ganglion: a retrograde axonal tracing study using wheat germ agglutinin conjugated with horseradish peroxidase. J Anesth. 1994;8:441–9.
11. Shen MJ, Hao-Che C, Park HW, George Akingba A, Chang PC, Zheng Z, et al. Low-level vagus nerve stimulation upregulates small conductance calcium-activated potassium channels in the stellate ganglion. Heart Rhythm. 2013;10(6):910–5. doi:10.1016/j.hrthm.2013.01.029.
12. Ogawa M, Zhou S, Tan AY, Song J, Gholmieh G, Fishbein MC, et al. Left stellate ganglion and vagal nerve activity and cardiac arrhythmias in ambulatory dogs with pacing-induced congestive heart failure. J Am Coll Cardiol. 2007;50(4):335–43. doi:10.1016/j.jacc.2007.03.045.
13. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in atrial fibrillation: pathophysiology and therapy. Circ Res. 2014;114(9):1500–15. doi:10.1161/circresaha.114.303772.
14. Tan AY, Li H, Wachsmann-Hogiu S, Chen LS, Chen PS, Fishbein MC. Autonomic innervation and segmental muscular disconnections at the human pulmonary vein-atrial junction: implications for catheter ablation of atrial-pulmonary vein junction. J Am Coll Cardiol. 2006;48(1):132–43.
15. Vracko R, Thorning D, Frederickson RG. Nerve fibers in human myocardial scars. Hum Pathol. 1991;22(2):138–46.
16. Vracko R, Thorning D, Frederickson RG. Fate of nerve fibers in necrotic, healing, and healed rat myocardium laboratory investigation. A J Tech Methods Pathol. 1990;63(4):490–501.
17. Cao JM, Chen LS, KenKnight BH, Ohara T, Lee MH, Tsai J, et al. Nerve sprouting and sudden cardiac death. Circ Res. 2000;86(7):816–21.
18. Miyauchi Y, al. e. Induction of atrial sympathetic nerve sprouting and increased vulnerability to atrial fibrillation by chronic left ventricular myocardial infarction. Circulation. 2001;104(II).
19. Tan AY, Zhou S, Ogawa M, Song J, Chu M, Li H, et al. Neural mechanisms of paroxysmal atrial fibrillation and paroxysmal atrial tachycardia in ambulatory canines. Circulation. 2008;118(9):916–25. doi:10.1161/circulationaha.108.776203.
20. Viskin S, Golovner M, Malov N, et al. Circadian variation of symptomatic paroxysmal atrial fibrillation. Data from almost 10 000 episodes. Eur Heart J. 1999;20:1429–34.
21. Sharifov OF, Fedorov VV, Beloshapko GG, Glukhov AV, Yushmanova AV, Rosenshtraukh LV. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J Am Coll Cardiol. 2004;43(3):483–90. doi:10.1016/j.jacc.2003.09.030.
22. Liu L, Nattel S. Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol. 1997;273(2 Pt 2):H805–16.
23. Nishida K, Maguy A, Sakabe M, Comtois P, Inoue H, Nattel S. The role of pulmonary veins vs. autonomic ganglia in different experimental substrates of canine atrial fibrillation. Cardiovasc Res. 2011;89(4):825–33. doi:10.1093/cvr/cvq332.
24. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke J Cereb Circ. 2005;36(6):1115–9. doi:10.1161/01.STR.0000166053.83476.4a.
25. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. doi:10.1093/eurheartj/ehq278.
26. Scherlag BJ, Patterson E, Po SS. The neural basis of atrial fibrillation. J Electrocardiol. 2006;39(4 Suppl):S180–3. doi:10.1016/j.jelectrocard.2006.05.021.
27. Wijffels MC, Kirchhof CJ, Dorland R, Power J, Allessie MA. Electrical remodeling due to atrial fibrillation in chronically instrumented conscious goats: roles of neurohumoral changes, ischemia, atrial stretch, and high rate of electrical activation. Circulation. 1997;96(10):3710–20.
28. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58(1):59–70.
29. Kapa S, Venkatachalam KL, Asirvatham SJ. The autonomic nervous system in cardiac electrophysiology: an elegant interaction and emerging concepts. Cardiol Rev. 2010;18(6):275–84. doi:10.1097/CRD.0b013e3181ebb152.
30. Bettoni M, Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation. 2002;105(23):2753–9.
31. Head GA. Central imidazoline- and alpha 2-receptors involved in the cardiovascular actions of centrally acting antihypertensive agents. Ann N Y Acad Sci. 1999;881:279–86.
32. Trenk D, Wagner F, Jahnchen E, Planitz V. Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol. 1987;27(12):988–93.
33. Kraft K, Vetter H. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: moxonidine versus captopril. J Cardiovasc Pharmacol. 1994;24 Suppl 1:S29–33.
34. Kuppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15(1):93–7.
35. Planitz V. Intraindividual comparison of moxonidine and prazosin in hypertensive patients. Eur J Clin Pharmacol. 1986;29(6):645–50.
36. Lepran I, Papp JG. Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol. 1994;24 Suppl 1:S9–15.
37. Mest HJ, Thomsen P, Raap A. Antiarrhythmic effect of the selective I1-imidazoline receptor modulator moxonidine on ouabain-induced cardiac arrhythmia in guinea pigs. Ann N Y Acad Sci. 1995;763:620–33.
38. Deftereos S, Giannopoulos G, Kossyvakis C, Efremidis M, Panagopoulou V, Raisakis K, et al. Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients. Am J Cardiol. 2013;112(5):684–7. doi:10.1016/j.amjcard.2013.04.049. First study to show that a reduction of sympathetic activation with administration of moxonidine resulted in a decrease in AF burden in hypertensive patients with paroxysmal AF.
39. Giannopoulos G, Kossyvakis C, Efremidis M, Katsivas A, Panagopoulou V, Doudoumis K, et al. Central sympathetic inhibition to reduce postablation atrial fibrillation recurrences in hypertensive patients: a randomized, controlled study. Circulation. 2014;130(16):1346–52. doi:10.1161/circulationaha.114.010999. First study to demonstrate that moxonidine reduce post-ablation recurrence of AF in patients with hypertension who underwent pulmonary vein isolation for drug-refractory paroxysmal AF.
40. Schachter M, Luszick J, Jager B, Verboom C, Sohlke E. Safety and tolerability of moxonidine in the treatment of hypertension. Drug Saf. 1998;19(3):191–203.
41. Edwards LP, Brown-Bryan TA, McLean L, Ernsberger P. Pharmacological properties of the central antihypertensive agent, moxonidine. Cardiovasc Ther. 2012;30(4):199–208. doi:10.1111/j.1755-5922.2011.00268.x.
42. Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5(5):659–67.
43. Pocock S, Wilhelmsen L, Dickstein K, Francis G, Wittes J. The data monitoring experience in the MOXCON trial. Eur Heart J. 2004;25(22):1974–8. doi:10.1016/j.ehj.2004.09.015.
44. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787–847. doi:10.1093/eurheartj/ehs104.
45. Honda N, Hirooka Y, Ito K, Matsukawa R, Shinohara K, Kishi T, et al. Moxonidine-induced central sympathoinhibition improves prognosis in rats with hypertensive heart failure. J Hypertens. 2013;31(11):2300–8. doi:10.1097/HJH.0b013e328364a2a1. discussion 8.
46. Ripley DP, Negrou K, Oliver JJ, Worthy G, Struthers AD, Plein S, et al. Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study. Clin Experiment Hyper (New York, NY: 1993). 2015;37(4):308–16. doi:10.3109/10641963.2014.960974.
47. Huggett RJ, Hogarth AJ, Mackintosh AF, Mary DA. Sympathetic nerve hyperactivity in non-diabetic offspring of patients with type 2 diabetes mellitus. Diabetologia. 2006;49(11):2741–4. doi:10.1007/s00125-006-0399-9.
48. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens. 1994;12(5):495–502.
49. Masuo K, Katsuya T, Kawaguchi H, Fu Y, Rakugi H, Ogihara T, et al. Beta2-adrenoceptor polymorphisms relate to obesity through blunted leptin-mediated sympathetic activation. Am J Hypertens. 2006;19(10):1084–91. doi:10.1016/j.amjhyper.2006.02.015.
50. Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42(4):474–80. doi:10.1161/01.hyp.0000091371.53502.d3.
51. Palatini P, Vriz O, Nesbitt S, Amerena J, Majahalme S, Valentini M, et al. Parental hyperdynamic circulation predicts insulin resistance in offspring: the Tecumseh Offspring Study. Hypertension. 1999;33(3):769–74.
52. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106(20):2533–6.
53. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 Pt 1):560–3.
54. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension. 2004;44(6):847–52. doi:10.1161/01.HYP.0000147893.08533.d8.
55. Lambert E, Sari CI, Dawood T, Nguyen J, McGrane M, Eikelis N, et al. Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension. 2010;56(3):351–8. doi:10.1161/hypertensionaha.110.155663.
56. Lambert E, Straznicky N, Eikelis N, Esler M, Dawood T, Masuo K, et al. Gender differences in sympathetic nervous activity: influence of body mass and blood pressure. J Hypertens. 2007;25(7):1411–9. doi:10.1097/HJH.0b013e3281053af4.
57. Lambert EA, Straznicky NE, Dixon JB, Lambert GW. Should the sympathetic nervous system be a target to improve cardiometabolic risk in obesity? Am J Physiol Heart Circ Physiol. 2015;309(2):H244–58. doi:10.1152/ajpheart.00096.2015.
58. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009;30(7):850–6. doi:10.1093/eurheartj/ehn573.
59. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab. 2003;88(11):5163–8. doi:10.1210/jc.2003-030698.
60. Sarin S, Wenger C, Marwaha A, Qureshi A, Go BD, Woomert CA, et al. Clinical significance of epicardial fat measured using cardiac multislice computed tomography. Am J Cardiol. 2008;102(6):767–71. doi:10.1016/j.amjcard.2008.04.058.
61. Heyer CM, Kagel T, Lemburg SP, Bauer TT, Nicolas V. Lipomatous hypertrophy of the interatrial septum: a prospective study of incidence, imaging findings, and clinical symptoms. Chest. 2003;124(6):2068–73.
62. Isner JM, Swan 2nd CS, Mikus JP, Carter BL. Lipomatous hypertrophy of the interatrial septum: in vivo diagnosis. Circulation. 1982;66(2):470–3.
63. Sato Y, Matsuo S, Kusama J, Kunimasa T, Yoda S, Matsumoto N, et al. Lipomatous hypertrophy of the interatrial septum presenting as sick sinus syndrome. Int J Cardiol. 2007;119(2):280–1. doi:10.1016/j.ijcard.2006.07.161.
64. Shirani J, Roberts WC. Clinical, electrocardiographic and morphologic features of massive fatty deposits (“lipomatous hypertrophy”) in the atrial septum. J Am Coll Cardiol. 1993;22(1):226–38.
65. Al Chekakie MO, Welles CC, Metoyer R, Ibrahim A, Shapira AR, Cytron J, et al. Pericardial fat is independently associated with human atrial fibrillation. J Am Coll Cardiol. 2010;56(10):784–8. doi:10.1016/j.jacc.2010.03.071.
66. Thanassoulis G, Massaro JM, O’Donnell CJ, Hoffmann U, Levy D, Ellinor PT, et al. Pericardial fat is associated with prevalent atrial fibrillation: The Framingham Heart Study. Circ Arrhythm Electrophysiol. 2010;3(4):345–50. doi:10.1161/circep.109.912055. Recent cross-sectional analysis of the Framingham Heart Study showing that higher pericardial fat volumes were associated with about 40% higher odds of prevalent AF.
67. Friedman DJ, Wang N, Meigs JB, Hoffmann U, Massaro JM, Fox CS, et al. Pericardial fat is associated with atrial conduction: the Framingham Heart Study. J Am Heart Assoc. 2014;3(2), e000477. doi:10.1161/jaha.113.000477.
68. Chao TF, Hung CL, Tsao HM, Lin YJ, Yun CH, Lai YH, et al. Epicardial adipose tissue thickness and ablation outcome of atrial fibrillation. PLoS One. 2013;8(9), e74926. doi:10.1371/journal.pone.0074926.
69. Wong CX, Abed HS, Molaee P, Nelson AJ, Brooks AG, Sharma G, et al. Pericardial fat is associated with atrial fibrillation severity and ablation outcome. J Am Coll Cardiol. 2011;57(17):1745–51. doi:10.1016/j.jacc.2010.11.045.
70. Fox CS, Gona P, Hoffmann U, Porter SA, Salton CJ, Massaro JM, et al. Pericardial fat, intrathoracic fat, and measures of left ventricular structure and function: the Framingham Heart Study. Circulation. 2009;119(12):1586–91. doi:10.1161/circulationaha.108.828970.
71. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108(20):2460–6. doi:10.1161/01.cir.0000099542.57313.c5.
72. 2015. RCMMedce, Study. ABEFTaPCADACC, Faghihi S1 V-FA, Parsaee M3, Saedi S1, Ghadrdoost B1.
73. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the heart and soul study. Am Heart J. 2008;155(2):303–9. doi:10.1016/j.ahj.2007.09.006.
74. Tselentakis EV, Woodford E, Chandy J, Gaudette GR, Saltman AE. Inflammation effects on the electrical properties of atrial tissue and inducibility of postoperative atrial fibrillation. J Surg Res. 2006;135(1):68–75. doi:10.1016/j.jss.2006.03.024.
75. Faghihi S, Vasheghani-Farahani A, Parsaee M, Saedi S, Ghadrdoost B. Association between epicardial fat thickness and premature coronary artery disease: a case control study. Res Cardiovas Med. 2015;4(2), e25679. doi:10.5812/cardiovascmed.4(2)2015.25679.
76. Haberka M, Gasior Z. A carotid extra-media thickness, PATIMA combined index and coronary artery disease: comparison with well-established indexes of carotid artery and fat depots. Atherosclerosis. 2015;243(1):307–13. doi:10.1016/j.atherosclerosis.2015.09.022.
77. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens Suppl Off J Int Soc Hyper. 1999;17(3):S29–35.
78. Sharma AM, Wagner T, Marsalek P. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study. J Hum Hypertens. 2004;18(9):669–75. doi:10.1038/sj.jhh.1001676.
79. Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006;8(4):456–65. doi:10.1111/j.1463-1326.2006.00606.x.
80. Chazova I, Schlaich MP. Improved hypertension control with the imidazoline agonist moxonidine in a multinational metabolic syndrome population: principal results of the MERSY study. Int J Hypertens. 2013;2013:541689. doi:10.1155/2013/541689.
81. Rajendran PS, Buch E, Shivkumar K. Marshaling the autonomic nervous system for treatment of atrial fibrillation. J Am Coll Cardiol. 2014;63(18):1902–3. doi:10.1016/j.jacc.2014.01.033.
82. Reichlin T, Michaud GF. Our approach to maximizing the durability of pulmonary vein isolation during a paroxysmal atrial fibrillation ablation procedure. J Cardiovasc Electrophysiol. 2012;23(11):1272–6. doi:10.1111/j.1540-8167.2012.02414.x.
83. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Heart Rhythm. 2012;9(4):632–96.e21. doi:10.1016/j.hrthm.2011.12.016.
84. Esler MD, Bohm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9. doi:10.1093/eurheartj/ehu209.
85. Esler MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka PA. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976–82. doi:10.1161/circulationaha.112.130880.
86. Howard JP, Nowbar AN, Francis DP. Size of blood pressure reduction from renal denervation: insights from meta-analysis of antihypertensive drug trials of 4,121 patients with focus on trial design: the CONVERGE report. Heart. 2013;99(21):1579–87. doi:10.1136/heartjnl-2013-304238.
87. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet (London, England). 2009;373(9671):1275–81. doi:10.1016/s0140-6736(09)60566-3.
88. Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the symplicity HTN-1 study. Lancet (London, England). 2014;383(9917):622–9. doi:10.1016/s0140-6736(13)62192-3.
89. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932–4. doi:10.1056/NEJMc0904179.
90. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet (London, England). 2010;376(9756):1903–9. doi:10.1016/s0140-6736(10)62039-9.
91. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940–6. doi:10.1161/circulationaha.110.991869.
92. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Bohm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol Off J German Cardiac Soc. 2011;100(12):1049–57. doi:10.1007/s00392-011-0335-y.
93. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559–65. doi:10.1161/hypertensionaha.111.173799.
94. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60(1):172–8. doi:10.1161/hypertensionaha.112.191965.
95. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61(1):225–31. doi:10.1161/hypertensionaha.111.00182.
96. Himmel F, Weil J, Reppel M, Mortensen K, Franzen K, Ansgar L, et al. Improved heart rate dynamics in patients undergoing percutaneous renal denervation. J Clin Hypertens (Greenwich). 2012;14(9):654–5. doi:10.1111/j.1751-7176.2012.00658.x.
97. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163–70. doi:10.1016/j.jacc.2012.05.036.
98. Joshi S, Choi AD, Kamath GS, Raiszadeh F, Marrero D, Badheka A, et al. Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings. J Cardiovasc Electrophysiol. 2009;20(10):1089–94. doi:10.1111/j.1540-8167.2009.01506.x.
99. Ahmed H, Miller MA, Dukkipati SR, Cammack S, Koruth JS, Gangireddy S, et al. Adjunctive renal sympathetic denervation to modify hypertension as upstream therapy in the treatment of atrial fibrillation (H-FIB) study: clinical background and study design. J Cardiovasc Electrophysiol. 2013;24(5):503–9. doi:10.1111/jce.12095.
100. Health USNIo. Adjunctive Renal Sympathetic Denervation to Modify Hypertension as Upstream Therapy in the Treatment of Atrial Fibrillation. https://clinicaltrials.gov/ct2/results?term=H-Fib&Search=Search. Accessed 30 October 2015.
101. Qiu M, Yin Y, Shan Q. Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial. Trials. 2013;14:168. doi:10.1186/1745-6215-14-168.
102. Pokushalov E, Romanov A, Katritsis DG, Artyomenko S, Bayramova S, Losik D, et al. Renal denervation for improving outcomes of catheter ablation in patients with atrial fibrillation and hypertension: early experience. Heart Rhythm. 2014;11(7):1131–8. doi:10.1016/j.hrthm.2014.03.055.
103. Vollmann D, Sossalla S, Schroeter MR, Zabel M. Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation. Clin Res Cardiol Off J German Cardiac Soc. 2013;102(4):315–8. doi:10.1007/s00392-012-0529-y.
104. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, et al. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol Off J German Cardiac Soc. 2012;101(1):63–7. doi:10.1007/s00392-011-0365-5. A first-in-man experience in 2 patients with chronic heart failure and electrical storm, in which RDN was performed as an experimental attempt to reduce VT occurrence.
105. Scholz EP, Raake P, Thomas D, Vogel B, Katus HA, Blessing E. Rescue renal sympathetic denervation in a patient with ventricular electrical storm refractory to endo- and epicardial catheter ablation. Clin Res Cardiol Off J German Cardiac Soc. 2015;104(1):79–84. doi:10.1007/s00392-014-0749-4.
106. Health USNIo. REnal SympathetiC Denervation to sUpprEss Ventricular Tachyarrhythmias. https://clinicaltrials.gov/ct2/results?term=rescue-vt. Accessed 26 october 2015.
107. Health USNIo. REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation. https://clinicaltrials.gov/ct2/results?term=RESET-VT&Search=Search. Accessed 26 october 2015.
108. Health USNIo. Renal denervation in patient undergoing VT ablation: combined renal denervation and VT ablation vs. simply VT ablation. https://clinicaltrials.gov/ct2/results?term=ardevat&Search=Search. Accessed 26 october 2015.
109. Esler M, Straznicky N, Eikelis N, Masuo K, Lambert G, Lambert E. Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension. 2006;48(5):787–96. doi:10.1161/01.hyp.0000242642.42177.49.
110. Esler M, In: Zanchetti A, Birkenhager W. Looking at the sympathetic nervous system as a primary source. In: Elsevier, editor. Handbook of Hypertension: Hypertension Research in the Twentieth Century. Amsterdam2004. p. 81-103.
111. Prichard BN, Graham BR, Owens CW. Moxonidine: a new antiadrenergic antihypertensive agent. J Hypertens Suppl Off J Int Soc Hyper. 1999;17(3):S41–54.
112. Prichard BN, Graham BR. The use of moxonidine in the treatment of hypertension. J Hypertens Suppl Off J Int Soc Hyper. 1997;15(1):S47–55.